Abstract:The last issue of the Journal of Obstetrics and Gynaecology included a case report from Yasmin and colleagues: ‘Early-onset epithelial ovarian cancer in a patient who had undergone oocyte donation’. There is an increasing literature linking ovarian cancer with infertility and infertility treatment, but the case described has some important differences—she was multiparous, had no past history of infertility (and as far as is known had not been exposed to clomiphene), had only two cycles of ovarian hyperstimulation for oocyte retrieval and donation, and the histology was of a serous adenocarcinoma. Some of the details are not available because HEFA regulations make them confidential, but we may presume that her ovaries were ultrasonically normal at that time. These points are made by the authors in their discussion. The case report adds some credence to the plight of Liz Tilberis, the former editor of Vogue, who believed that her fertility treatment caused her to develop ovarian cancer. Bamford and Steele (1982) reported from the Middlesex Hospital, London, the history of a 32-yearold nulliparous woman who had undergone eight cycles of ovulation induction with gonadotrophins, followed by a 2-year gap and a further three cycles. A 4-cm ovarian cyst was noted at the time, which increased to 25 cm diameter within a month. Emergency laparotomy was performed and an ovarian endometrioid adenocarcinoma was found, along with atypical endometrial hyperplasia and adenocarcinoma. Goldberg and Runowicz (1992) reported three cases of ovarian low malignant potential tumours following ovulation induction; all three were serous in histological type. Each of the patients had received two or three cycles of Pergonal for gonadotrophin induction of ovulation or for in vitro fertilisation. Land (1993) reviewed the literature up to that time and reported on ten cases of ovarian neoplasia developing during or soon after ovulation induction therapy. The patients were young, ranging between 22 and 38 years, and seven of the 10 were borderline or low malignant potential tumours. Apart from the case reported by Bamford and Steele, the histology on the other nine was serous or serous papillary type. Rossing et al. (1994) reviewed a cohort of 3837 women from Seattle who had been evaluated for infertility between 1974 and 1985. Eleven were subsequently found to have ovarian tumours but two were granulosa cell tumours, five were borderline tumours, and only four were epithelial ovarian cancers. The authors demonstrated an increased risk with clomiphene use, particularly if more than 12 cycles were used. The five borderline tumours were two serous papillary, two mucinous and one mucinous papillary histological type, while the four invasive tumours were two mucinous, one endometrioid and one adenocarcinoma without further classification. It should be noted that the Committee on Safety of Medicines now recommends, on the basis of Rossing’s data, that clomiphene should not normally be used for more than six cycles. Other cases continue to be reported (e.g. Hull et al., 1996; Unkila-Kallio et al., 1997) and the majority are of serous papillary type, although malignant teratoma, granulosa cell tumour and mucinous adenocarcinoma are included. However, the argument is not all one way, and several large studies have reported negative associations. Franceschi et al. (1994) analysed the relationship between fertility drugs and ovarian cancer in a case– control study (195 epithelial ovarian cancer cases and 1339 control cases) in four areas in Italy—they could not establish a role for ovarian stimulation from their data. Venn et al. (1995) reviewed 5564 women who had in vitro fertilisation with ovarian stimulation, and 4794 ‘unexposed’ women, i.e. had IVF without ovarian stimulation or were not treated, and in a subsequent report (Venn et al., 1999) included 29 700 women, 20 656 exposed and 9044 unexposed to fertility drugs (in 10 Australian IVF clinics). On review, the incidence of ovarian cancer was not greater than expected (by standardised incidence ratios) and no difference between exposed and unexposed women. Mosgaard et al. (1997) summarised the current position:

[Evaluation of the performance of Coulter S+II].

High-Grade Dysplasia in Resected Main-Duct Intraductal Papillary Mucinous Neoplasm (MD-IPMN) is Associated with an Increased Risk of Subsequent Pancreatic Cancer

Elevated Percentage of L-Selectin on Peripheral Blood Τ Lymphocytes (PBTLs) in Children and Adolescents with Type 1 Diabetes Mellitus and Vascular Complications

Recurrence patterns after surgical resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas; a multicenter, retrospective study of 1074 IPMN patients by the Japan Pancreas Society

Phylogenetic Relationships of Pseudorasbora, Pseudopungtungia, and Pungtungia (Teleostei; Cypriniformes; Gobioninae) Inferred from Multiple Nuclear Gene Sequences

Qualitative evaluation of Project P.A.T.H.S. in Hong Kong: focus groups based on Secondary 3 program implementers

Survival Analysis and Risk for Progression of Intraductal Papillary Mucinous Neoplasia of the Pancreas (IPMN) Under Surveillance: A Single-Institution Experience

Histopathological evaluation of resected intraductal papillary mucinous neoplasms reveals distinct patterns of invasion in associated carcinomas

[Standards, options and recommendations for the use of medical analgesics for the treatment of pain arising from excess nociception in adults with cancer (update 2002)].

Experience with 208 resections for intraductal papillary mucinous neoplasm of the pancreas

Epithelial ovarian cancer and infertility treatment

Impossible Dreams

Risk of the Watch-and-Wait Concept in Surgical Treatment of Intraductal Papillary Mucinous Neoplasm

Purification of multiple heat shock proteins from a single tumor sample.

Consequences of a Surveillance Strategy for Side-branch Intraductal Pancreatic Mucinous Neoplasms: Long-term Follow-up of One Thousand Cysts

Effects of adriamycin on chronic cardiotoxicity in selenium-deficient rats

Subtype of intraductal papillary mucinous neoplasm of the pancreas is important to the development of metachronous high-risk lesions after pancreatectomy

An Overview for Clinicians on Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas

Risk of Recurrence After Surgical Resection for Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasia (IPMN) With Patterns of Distribution and Treatment: An International, Multicenter, Observational Study (ADENO-IPMN Study)

Alfentanil partition coefficient.

Oncological Outcomes and Patterns of Recurrence after the Surgical Resection of an Invasive Intraductal Papillary Mucinous Neoplasm versus Primary Pancreatic Ductal Adenocarcinoma: An Analysis from the German Cancer Registry Group of the Society of German Tumor Centers